300816-11-9
300816-11-9
Chemical Structure
Nullscript
- CAS No.: 300816-11-9
- Formula:C16H14N2O4
- Molecular Weight:298.29
IUPAC Name: 4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxybutanamide
InChIKey: GBPSCCPAXYTNMB-UHFFFAOYSA-N
SMILES: O=C(N(C1=O)CCCC(NO)=O)C2=CC=CC3=CC=CC1=C23
Biological Activity: Nullscript is a negative control for Scriptaid. Nullscript is a known inactive analog of Scriptaid[1]. Scriptaid is a representative HDAC inhibitor[2]. Nullscript inhibits Cryptosporidium (C. parvum) growth with the IC50 value of 2.1 μM[3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nullscript | 98.18% | Nullscript is a negative control for Scriptaid. Nullscript is a known inactive analog of Scriptaid. Scriptaid is a representative HDAC inhibitor. Nullscript inhibits Cryptosporidium (C. parvum) growth with the IC50 value of 2.1 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Min Tong, et al. Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells. Biochem Pharmacol. 2006 Sep 14;72(6):701-9. [Content Brief]
- [2]. Judith Clancy Keen, et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat. 2003 [Content Brief]
- [3]. Fumi Murakoshi, et al. Nullscript inhibits Cryptosporidium and Toxoplasma growth. Int J Parasitol Drugs Drug Resist. 2020 Dec;14:159-166. [Content Brief]
